{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:36:39Z","timestamp":1765805799227,"version":"3.40.5"},"reference-count":136,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["tmreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.tmrv.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T07:01:33Z","timestamp":1456210893000},"page":"53-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium"],"prefix":"10.1016","volume":"30","author":[{"given":"Geraldine M.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew W.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Solh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Golder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Fearon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-8189","authenticated-orcid":false,"given":"William P.","family":"Sheffield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2016.02.003_bb0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.tmrv.2009.06.004","article-title":"Blood group antigens and normal red blood cell physiology: A Canadian Blood Services Research and Development symposium","volume":"23","author":"Lin","year":"2009","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tmrv.2011.07.003","article-title":"Red blood cell storage lesions and related transfusion issues: A Canadian Blood Services Research and Development symposium","volume":"26","author":"Pavenski","year":"2012","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tmrv.2010.05.005","article-title":"Transfusion-related acute lung injury (TRALI): A Canadian Blood Services Research and Development Symposium","volume":"24","author":"Saidenberg","year":"2010","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tmrv.2005.04.005","article-title":"Blood group biochemistry: A Canadian Blood Services Research and Development Symposium","volume":"19","author":"Sheffield","year":"2005","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tmrv.2007.05.007","article-title":"Cellular therapies: A Canadian Blood Services Research and Development Symposium","volume":"21","author":"Shehata","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.tmrv.2006.05.008","article-title":"Platelet immunopathology and therapy: A Canadian Blood Services Research and Development Symposium","volume":"20","author":"Tinmouth","year":"2006","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0035","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tmrv.2014.01.002","article-title":"Platelet utilization: A Canadian Blood Services Research and Development Symposium","volume":"28","author":"Webert","year":"2014","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.tmrv.2015.03.003","article-title":"Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium","volume":"29","author":"Zeller","year":"2015","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1423-0410.2012.01584.x","article-title":"Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services","volume":"103","author":"O'Brien","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0050","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1111\/j.1537-2995.2006.01030.x","article-title":"Transfusion-associated transmission of West Nile virus, United States 2003 through 2005","volume":"46","author":"Montgomery","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0055","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1537-2995.2009.02550.x","article-title":"West Nile virus in 2006 and 2007: the Canadian Blood Services' experience","volume":"50","author":"O'Brien","year":"2010","journal-title":"Transfusion"},{"author":"World Health Organization","key":"10.1016\/j.tmrv.2016.02.003_bb0060"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0065","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1086\/605091","article-title":"An estimate of the burden of Chagas disease in the United States","volume":"49","author":"Bern","year":"2009","journal-title":"Clin Infect Dis"},{"author":"AABB","key":"10.1016\/j.tmrv.2016.02.003_bb0070"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0075","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/trf.12219","article-title":"Evaluation of selective screening of donors for antibody to Trypanosoma cruzi: Seroprevalence of donors who answer \u201cno\u201d to risk questions","volume":"54","author":"O'Brien","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0080","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMra1202018","article-title":"Human babesiosis","volume":"366","author":"Vannier","year":"2012","journal-title":"N Engl J Med"},{"author":"Food and Drug Administration","key":"10.1016\/j.tmrv.2016.02.003_bb0085"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0090","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/0003-4819-155-8-201110180-00362","article-title":"Transfusion-associated babesiosis in the United States: A description of cases","volume":"155","author":"Herwaldt","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0095","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(14)61034-5","article-title":"Hepatitis E virus in blood components: A prevalence and transmission study in southeast England","volume":"384","author":"Hewitt","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0100","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(14)60185-9","article-title":"Chikungunya in the Americas","volume":"383","author":"Leparc-Goffart","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0105","doi-asserted-by":"crossref","first-page":"e0131282","DOI":"10.1371\/journal.pone.0131282","article-title":"Different Ecological Niches for Ticks of Public Health Significance in Canada","volume":"10","author":"Gabriele-Rivet","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/trf.13339","article-title":"Seroprevalence of Babesia microti infection in Canadian blood donors","volume":"56","author":"O'Brien","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tmrv.2011.05.002","article-title":"Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety","volume":"25","author":"Leach Bennett","year":"2011","journal-title":"Transfus Med Rev"},{"author":"Alliance of Blood Operators","key":"10.1016\/j.tmrv.2016.02.003_bb0120"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1423-0410.2011.01526.x","article-title":"Risk-based decision-making for blood safety: preliminary report of a consensus conference","volume":"101","author":"Stein","year":"2011","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/trf.12569","article-title":"How safe is safe enough, who decides and how? From a zero-risk paradigm to risk-based decision making","volume":"54","author":"Menitove","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.12031","article-title":"Emerging pathogens and their implications for the blood supply and transfusion transmitted infections","volume":"159","author":"Dodd","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0140","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4161\/pri.29237","article-title":"Variant CJD. 18 years of research and surveillance","volume":"8","author":"Diack","year":"2014","journal-title":"Prion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0145","doi-asserted-by":"crossref","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0150","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/v7030996","article-title":"Identification of new respiratory viruses in the new millennium","volume":"7","author":"Berry","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0155","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jfma.2015.02.003","article-title":"Hepatitis E: A disease of reemerging importance","volume":"114","author":"Sridhar","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0160","series-title":"Transfusion-transmitted viral diseases","first-page":"37","article-title":"Transmission of human immunodeficiency virus (HIV) by blood and blood components","author":"Allen","year":"1987"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tmrv.2015.03.001","article-title":"Keeping Blood Transfusion Safe From West Nile Virus: American Red Cross Experience, 2003 to 2012","volume":"29","author":"Dodd","year":"2015","journal-title":"Transfus Med Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.tmrv.2016.02.003_bb0170","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1111\/j.1537-2995.2009.02279.x","article-title":"Emerging infectious disease agents and their potential threat to transfusion safety","volume":"49","author":"Stramer","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0175","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/trf.12371","article-title":"AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup: Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress","volume":"53","author":"Stramer","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature15369","article-title":"Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy","volume":"525","author":"Jaunmuktane","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0185","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0190","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1537-2995.2012.03566.x","article-title":"Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico","volume":"52","author":"Stramer","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0195","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/trf.12790","article-title":"Chikungunya virus: new risk to transfusion safety in the Americas","volume":"54","author":"Petersen","year":"2014","journal-title":"Transfusion"},{"author":"Cerus Corporation","key":"10.1016\/j.tmrv.2016.02.003_bb0200"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0205","first-page":"210","article-title":"Ebola virus circulation in Africa: A balance between clinical expression and epidemiological silence","volume":"98","author":"Gonzalez","year":"2005","journal-title":"Bull Soc Pathol Exot"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/path.4456","article-title":"Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses","volume":"235","author":"Martines","year":"2015","journal-title":"J Pathol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.09.001","article-title":"Clinical features and pathobiology of Ebolavirus infection","volume":"55","author":"Ansari","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2015.01.002","article-title":"Ebola virus disease in Africa: epidemiology and nosocomial transmission","volume":"90","author":"Shears","year":"2015","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0225","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(15)70106-4","article-title":"Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?","volume":"15","author":"Lanini","year":"2015","journal-title":"Lancet Infect Dis"},{"author":"World Health Organization","key":"10.1016\/j.tmrv.2016.02.003_bb0230"},{"year":"2014","author":"Belluz","series-title":"Why is Ebola less deadly in America than in Africa?","key":"10.1016\/j.tmrv.2016.02.003_bb0235"},{"year":"2014","author":"Ginsburg","series-title":"How saving West African forests might have prevented the Ebola epidemic","key":"10.1016\/j.tmrv.2016.02.003_bb0240"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0245","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(15)60644-4","article-title":"A retrospective and prospective analysis of the west African Ebola virus disease epidemic: Robust national health systems at the foundation and an empowered WHO at the apex","volume":"385","author":"Gostin","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0250","first-page":"179","article-title":"Community quarantine to interrupt Ebola virus transmission - Mawah Village, Bong County, Liberia, August-October, 2014","volume":"64","author":"Nyenswah","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0255","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"author":"World Health Organization","key":"10.1016\/j.tmrv.2016.02.003_bb0260"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0265","doi-asserted-by":"crossref","first-page":"e0003652","DOI":"10.1371\/journal.pntd.0003652","article-title":"What factors might have led to the emergence of Ebola in West Africa?","volume":"9","author":"Alexander","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0270","doi-asserted-by":"crossref","first-page":"307rv305","DOI":"10.1126\/scitranslmed.aab0191","article-title":"Lessons from Ebola: Improving infectious disease surveillance to inform outbreak management","volume":"7","author":"Woolhouse","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/jama.2013.7518","article-title":"The paradox of disease prevention: celebrated in principle, resisted in practice","volume":"310","author":"Fineberg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0280","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(15)61233-8","article-title":"Strategies to prevent future Ebola epidemics","volume":"386","author":"Fallah","year":"2015","journal-title":"Lancet"},{"year":"2015","author":"Bennett","series-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","key":"10.1016\/j.tmrv.2016.02.003_bb0285"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2307\/3570877","article-title":"The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice","volume":"13","author":"McCulloch","year":"1960","journal-title":"Radiat Res"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0295","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood.V51.3.527.527","article-title":"Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties","volume":"51","author":"Gregory","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0300","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.transci.2011.06.007","article-title":"In vitro production of red blood cells","volume":"45","author":"Mountford","year":"2011","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0305","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood.V73.1.100.100","article-title":"Proliferation and maturation of human erythroid progenitors in liquid culture","volume":"73","author":"Fibach","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/stem.5530090108","article-title":"Growth of human normal erythroid progenitors in liquid culture: A comparison with colony growth in semisolid culture","volume":"9","author":"Fibach","year":"1991","journal-title":"Int J Cell Cloning"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-59745-060-7_8","article-title":"Ex vivo generation of human red blood cells: A new advance in stem cell engineering","volume":"482","author":"Douay","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0320","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0325","doi-asserted-by":"crossref","first-page":"10716","DOI":"10.1073\/pnas.191362598","article-title":"Hematopoietic colony-forming cells derived from human embryonic stem cells","volume":"98","author":"Kaufman","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0330","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1038\/nprot.2007.418","article-title":"Induction of pluripotent stem cells from fibroblast cultures","volume":"2","author":"Takahashi","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0335","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0340","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1749-6632.2009.04606.x","article-title":"Hematopoietic development from human induced pluripotent stem cells","volume":"1176","author":"Lengerke","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0345","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/stem.20080922","article-title":"Hematopoietic and endothelial differentiation of human induced pluripotent stem cells","volume":"27","author":"Choi","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0350","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3324\/haematol.2011.055566","article-title":"Human induced pluripotent stem cells can reach complete terminal maturation: In vivo and in vitro evidence in the erythropoietic differentiation model","volume":"97","author":"Kobari","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0355","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/mt.2013.201","article-title":"Extensive ex vivo expansion of functional human erythroid precursors established from umbilical cord blood cells by defined factors","volume":"22","author":"Huang","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0360","doi-asserted-by":"crossref","first-page":"791604","DOI":"10.4061\/2011\/791604","article-title":"Generation and characterization of erythroid cells from human embryonic stem cells and induced pluripotent stem cells: An overview","volume":"2011","author":"Chang","year":"2011","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0365","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOH.0b013e3283476129","article-title":"Red blood cells from induced pluripotent stem cells: Hurdles and developments","volume":"18","author":"Mazurier","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0370","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2014.110155","article-title":"Induction of adult levels of beta-globin in human erythroid cells that intrinsically express embryonic or fetal globin by transduction with KLF1 and BCL11A-XL","volume":"99","author":"Trakarnsanga","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0375","doi-asserted-by":"crossref","first-page":"e59890","DOI":"10.1371\/journal.pone.0059890","article-title":"Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells","volume":"8","author":"Kurita","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0380","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.23414","article-title":"In vitro generated Rh(null) red cells recapitulate the in vivo deficiency: A model for rare blood group phenotypes and erythroid membrane disorders","volume":"88","author":"Cambot","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0385","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1182\/blood-2011-06-362038","article-title":"Proof of principle for transfusion of in vitro-generated red blood cells","volume":"118","author":"Giarratana","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0390","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nbt.2014.07.008","article-title":"Identifying viable regulatory and innovation pathways for regenerative medicine: A case study of cultured red blood cells","volume":"32","author":"Mittra","year":"2015","journal-title":"N Biotechnol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0395","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"PNAS"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fmicb.2014.00305","article-title":"DNA polymerases drive DNA sequencing-by-synthesis technologies: both past and present","volume":"5","author":"Chen","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0405","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/290457a0","article-title":"Sequence and organization of the human mitochondrial genome","volume":"290","author":"Anderson","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0410","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0415","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The sequence of the human genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-394287-6.00001-X","article-title":"Next generation sequencing methodologies--an overview","volume":"89","author":"Pickrell","year":"2012","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0425","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13353-011-0057-x","article-title":"Sequencing technologies and genome sequencing","volume":"52","author":"Pareek","year":"2011","journal-title":"J Appl Genet"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0430","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nmeth.3244","article-title":"MinION takes center stage","volume":"12","author":"Rusk","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0435","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1101\/gr.171934.113","article-title":"A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples","volume":"24","author":"Naccache","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0440","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa1401268","article-title":"Actionable diagnosis of neuroleptospirosis by next-generation sequencing","volume":"370","author":"Wilson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0445","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/ciu912","article-title":"Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing","volume":"60","author":"Naccache","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0450","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13073-015-0220-9","article-title":"Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis","volume":"7","author":"Greninger","year":"2015","journal-title":"Genome Med"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0455","doi-asserted-by":"crossref","first-page":"10264","DOI":"10.1073\/pnas.1303744110","article-title":"Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing","volume":"110","author":"Xu","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0460","doi-asserted-by":"crossref","first-page":"11966","DOI":"10.1128\/JVI.02323-13","article-title":"The perils of pathogen discovery: Origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns","volume":"87","author":"Naccache","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0465","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/vox.12098","article-title":"Bacterial contamination in platelet concentrates","volume":"106","author":"Pietersz","year":"2014","journal-title":"Vox Sang"},{"author":"AABB","key":"10.1016\/j.tmrv.2016.02.003_bb0470"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0475","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1423-0410.2012.01662.x","article-title":"Component pathogen inactivation: a critical review","volume":"104","author":"Prowse","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0480","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2002-03-0932","article-title":"Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial","volume":"101","author":"van Rhenen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0485","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1537-2995.2005.00639.x","article-title":"Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: The SPRINT trial","volume":"45","author":"Snyder","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0490","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1537-2995.2010.02694.x","article-title":"A randomized controlled clinical trial evaluating the performance and safety of platelets treated with Mirasol pathogen reduction technology","volume":"50","author":"Mirasol Clinical Evaluation Study Group","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0495","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-12-4443","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial","volume":"104","author":"McCullough","year":"2004","journal-title":"Blood"},{"author":"Sanquin","key":"10.1016\/j.tmrv.2016.02.003_bb0500"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0505","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1423-0410.2011.01555.x","article-title":"Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system","volume":"102","author":"Vamvakas","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0510","first-page":"Cd009072","article-title":"Pathogen-reduced platelets for the prevention of bleeding","volume":"3","author":"Butler","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0515","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/trf.13137","article-title":"Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro","volume":"55","author":"Van Aelst","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0520","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.transci.2011.10.025","article-title":"Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction","volume":"46","author":"Tauszig","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0525","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/vox.12173","article-title":"Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light","volume":"107","author":"Bakkour","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0530","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1537-2995.2012.03854.x","article-title":"Pathogen inactivation of platelets using ultraviolet C light: Effect on in vitro function and recovery and survival of platelets","volume":"53","author":"Bashir","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0535","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.transci.2009.01.013","article-title":"Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study","volume":"40","author":"Picker","year":"2009","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0540","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000403245","article-title":"Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-kappaB Activation","volume":"42","author":"Johnson","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0545","doi-asserted-by":"crossref","first-page":"e0133070","DOI":"10.1371\/journal.pone.0133070","article-title":"Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems","volume":"10","author":"Osman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0550","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/09537104.2014.898178","article-title":"Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function","volume":"26","author":"Osman","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0555","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tmrv.2014.02.002","article-title":"Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus","volume":"28","author":"Prudent","year":"2014","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0560","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/trf.12905","article-title":"p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment","volume":"55","author":"Chen","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0565","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1111\/trf.12173","article-title":"Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment","volume":"53","author":"Schubert","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0570","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000324458","article-title":"Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates","volume":"38","author":"Henschler","year":"2011","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0575","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1537-2995.2004.03355.x","article-title":"Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light","volume":"44","author":"Ruane","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0580","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1537-2995.2011.03285.x","article-title":"Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood","volume":"52","author":"Tonnetti","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0585","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1537-2995.2012.03791.x","article-title":"Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood","volume":"53","author":"Tonnetti","year":"2013","journal-title":"Transfusion"},{"issue":"Suppl. 1","key":"10.1016\/j.tmrv.2016.02.003_bb0590","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/SHK.0000000000000280","article-title":"Treatment of Whole Blood With Riboflavin and UV Light: Impact on Malaria Parasite Viability and Whole Blood Storage","volume":"44","author":"Owusu-Ofori","year":"2015","journal-title":"Shock"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0595","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1537-2995.2010.03027.x","article-title":"In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood","volume":"51","author":"Cancelas","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0600","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/trf.12895","article-title":"Whole blood treated with riboflavin and ultraviolet light: Quality assessment of all blood components produced by the buffy coat method","volume":"55","author":"Schubert","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0605","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/trf.13080","article-title":"Alliance of Blood Operators Risk-Based Decision-Making I. Health economics and outcomes methods in risk-based decision-making for blood safety","volume":"55","author":"Custer","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0610","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1111\/trf.12805","article-title":"Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply","volume":"54","author":"Goodell","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0615","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1537-2995.2006.00828.x","article-title":"Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands","volume":"46","author":"Janssen","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0620","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/S0149-2918(03)80288-6","article-title":"Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States","volume":"25","author":"Bell","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0625","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1537-2995.2010.02704.x","article-title":"The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model","volume":"50","author":"Custer","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0630","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000371664","article-title":"Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis","volume":"42","author":"Agapova","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0635","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.tracli.2011.05.004","article-title":"Pathogen reduction: State of reflection in Ireland","volume":"18","author":"Murphy","year":"2011","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0640","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000346309","article-title":"Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates","volume":"36","author":"Berger","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0645","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/trf.12232","article-title":"Reducing the financial impact of pathogen inactivation technology for platelet components: Our experience","volume":"54","author":"Girona-Llobera","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0650","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1537-2995.2006.00832.x","article-title":"Variation of platelet production and discard rates in 17 blood centers representing 10 European countries from 2000 to 2002","volume":"46","author":"Veihola","year":"2006","journal-title":"Transfusion"},{"author":"Cerus Corporation","key":"10.1016\/j.tmrv.2016.02.003_bb0655"},{"year":"2012","author":"TerumoBCT","series-title":"Mirasol pathogen reduction technology system","key":"10.1016\/j.tmrv.2016.02.003_bb0660"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0665","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000323786","article-title":"Main Properties of the Theraflex MB-Plasma System for Pathogen Reduction","volume":"38","author":"Seghatchian","year":"2011","journal-title":"Transfus Med Hemother"},{"author":"Macopharma","key":"10.1016\/j.tmrv.2016.02.003_bb0670"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0675","series-title":"Use of Solvent\/Detergent-Treated Human Plasma (Octaplas): Pilot Project","article-title":"CADTH Optimal Use Reports","author":"Canadian Agency for Drugs and Technologies in Health","year":"2011"},{"key":"10.1016\/j.tmrv.2016.02.003_bb0680","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.transci.2012.01.008","article-title":"Characteristics of the Theraflex UV-Platelets pathogen inactivation system - An update","volume":"46","author":"Seghatchian","year":"2012","journal-title":"Transfus Apher Sci"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796316300050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796316300050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T14:56:17Z","timestamp":1718376977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796316300050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0887796316300050"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2016.02.003","relation":{},"ISSN":["0887-7963"],"issn-type":[{"type":"print","value":"0887-7963"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}